Congenital malformations of newborn infants after clomiphene-induced ovulation

Fertility and sterility, 40(2), 187-189

DOI 10.1016/s0015-0282(16)47235-3 PMID 6873315 Source

Abstract

The effect of clomiphene citrate (CC) on the incidence of congenital malformations in newborn infants was assessed from the outcome of 1034 pregnancies after CC-induced ovulation recorded at nine university hospitals in a 5-year period. Of these pregnancies, 14.2% ended in abortion, 0.5% in ectopic pregnancy, 0.1% in molar pregnancy, and 1.6% in stillbirth. In all, 935 infants were born, and 21 (2.3%) showed visible malformations. This incidence of malformations was not significantly different from that in 30,033 infants (1.7%) after spontaneous ovulation (spontaneous ovulation group), and the types of malformations after CC treatment were similar to e those in the spontaneous ovulation group. These data indicate that CC has no teratogenic effect.

Topics

clomiphene birth defects risk, clomid congenital malformations, ovulation induction teratogenic effects, clomiphene citrate safety pregnancy, birth defects after fertility drugs, clomid induced ovulation outcomes, congenital abnormalities clomiphene treatment, ovulation induction fetal outcomes, clomiphene teratogenicity study, fertility medication birth defect risk

Cite this article

Kurachi, K., Aono, T., Minagawa, J., & Miyake, A. (1983). Congenital malformations of newborn infants after clomiphene-induced ovulation. *Fertility and sterility*, *40*(2), 187-189. https://doi.org/10.1016/s0015-0282(16)47235-3

Related articles